Published in Vaccine Weekly, January 24th, 2001
Cancer vaccines that have been under investigation by BioPulse previously used only patient-specific tumor antigens. This approach provides a customized and specific vaccine product for each patient. The new tumor-specific vaccines use a combination of tumor antigens designed to target a class of tumors. This strategy potentially allows for a single...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly